Kymera Therapeutics Inc (KYMR) — Cash Flow Reinvestment Rate

Latest as of December 2023: 3.80x

Kymera Therapeutics Inc (KYMR) has a Cash Flow Reinvestment Rate of 3.80x as of December 2023, reinvesting $30.58 Million (capex $11.62 Million plus investments $18.95 Million) from operating cash flow of $8.04 Million. Explore how efficiently does Kymera Therapeutics Inc generate cash to assess how effectively this company generates cash.

Reinvestment Rate

3.80x
(Capex + Investments) / Operating CF

Total Reinvested

$30.58 Million
Capex + Investments

Operating Cash Flow

$8.04 Million
USD

Capital Expenditures

$11.62 Million
USD

Kymera Therapeutics Inc Cash Flow Reinvestment Rate (2019–2020)

Historical reinvestment intensity for Kymera Therapeutics Inc across 2 annual periods. Explore KYMR strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Kymera Therapeutics Inc (2019–2020)

Year-by-year capital reinvestment analysis for Kymera Therapeutics Inc. For live market cap and broader valuation context, see Kymera Therapeutics Inc (KYMR) total market value.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2020 4.90x $431.68 Million $88.13 Million $9.10 Million ▲ +432.0%
2019 0.92x $16.49 Million $17.91 Million $532.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow